Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Effects of GLP-1 Receptor Agonists in Type 2 Diabetes
NCT05990374Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Aug 2023
- Primary completion
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, triple-blind trial of ebenatide in type 2 diabetes mellitus (T2DM) and obesity (7 arms), sponsored by Nanjing First Hospital. Primary endpoint: Effects of different GLP-1 on blood glucose at 4 years. Status: unknown.
02
Drugs
ebenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05990374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990374.